Orphan Designation for ADPKD Treatment Marks Rare Disease Breakthrough
MONMOUTH, N.J., Sept. 18, 2025 A new investigational therapy, JD-004, has received Orphan Drug Designation (ODD) from the U.S. Food...
clinical trials
Advertisement
Wheeler Bio and MindImmune Partner on Alzheimer’s Therapy MITI-101
OKLAHOMA CITY, Sept. 17, 2025 – Wheeler Bio, Inc., a U.S.-based contract development and manufacturing organization (CDMO), announced today...
Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
AMO Pharma Reports Long-Term Safety Data of AMO-02 in DM1
LONDON, Sept. 15, 2025 – AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company dedicated to rare genetic...
Silexion’s SIL204 Shows Preclinical Promise in Pancreatic Cancer
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
Advertisements
Merck’s CAPVAXIVE Shows Strong Immune Response in Children
RAHWAY, N.J. – September 11, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada,...
FDA Grants Breakthrough Therapy Status to Olomorasib for Lung Cancer
INDIANAPOLIS, Sept. 4, 2025 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib,...
Atossa Pursues FDA Path for Low-Dose (Z)-Endoxifen in Breast Cancer Prevention
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
UK Approves Once-Monthly Octreotide Injection for Acromegaly Care
Lund, Sweden — August 28, 2025 — The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval...
Precision Robotic CERTA Access System Records First U.S. Clinical Outcomes
Fort Lauderdale, FL – September 4, 2025 – The first U.S. clinical cases using the CERTA™ Access System, a...
Advertisement
